靶向人端粒酶逆转录酶T细胞表位肽的治疗性癌症疫苗研究进展

Cancer therapeutic vaccines targeting hTERT-derived T-cell epitope peptide: Advances in researches

人端粒酶逆转录酶(hTERT)是人端粒酶的催化亚单位,正常成熟组织中基本无表达,而在多数恶性肿瘤中高表达,而使其成为恶性肿瘤特异性疫苗免疫治疗的首选抗原。T细胞表位肽疫苗是用抗原的T细胞表位制备的疫苗,在肿瘤免疫治疗中有其独特的优势。hTERT的T细胞表位肽疫苗可诱导机体产生特异性免疫应答,在小鼠体内显示了抗肿瘤效应,并已进入人体试验阶段,显示出较好的应用前景。文中就hTERT的T细胞表位肽疫苗在恶性肿瘤中的免疫治疗的研究进展作一综述。

Human telomerase reverse transcriptase （hTERT）, a catalytic subunit of telomerase, is highly expressed in a vast majority of cancer cells, but not in most normal adult cells, which makes it a broadly applicable molecular target for cancer immunotherapy. T cell epitope-based vaccines make use of T-cell epitopes from tumor antigens, and have its own unique advantages in cancer immunotherapy. The T-cell epitope peptide vaccine derived from hTERT can efficiently evoke specific cytotoxic T lymphocytes （CTL） responses, and has exhibited its anti-tumor effect in vivo in mice. Now it has already been put into experiment on human beings and displayed a good application prospect.